

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

B6.129S2-Cd8a^{tm1Mak}/J

RRID:IMSR_JAX:002665

Type: Organism

Proper Citation

RRID:IMSR_JAX:002665

Organism Information

URL: <https://www.jax.org/strain/002665>

Proper Citation: RRID:IMSR_JAX:002665

Description: Mus musculus with name B6.129S2-Cd8a^{tm1Mak}/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: CD8 subunit alpha; mutant strain|congenic strain: Cd8a

Affected Gene: CD8 subunit alpha

Genomic Alteration: targeted mutation 1; Tak Mak

Catalog Number: JAX:002665

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.129S2-Cd8a^{tm1Mak}/J

Record Creation Time: 20250513T053634+0000

Record Last Update: 20260808T050835+0000

Ratings and Alerts

No rating or validation information has been found for B6.129S2-Cd8a^{tm1Mak}/J.

No alerts have been found for B6.129S2-Cd8a^{tm1Mak}/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 99 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Schmiechen ZC, et al. (2026) Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. *Science immunology*, 11(120), eadz4302.

Ökten AB, et al. (2026) IgA is necessary and sufficient to prevent norovirus infection in mice. *Science translational medicine*, 18(855), eaeb4878.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. *Cell reports*, 44(6), 115800.

Herrmann C, et al. (2025) Environmental stress drives clearance of a persistent enteric virus in mice. *Nature microbiology*, 10(8), 1975.

Sharma P, et al. (2025) Smoking-induced gut microbial dysbiosis mediates cancer progression through modulation of anti-tumor immune response. *iScience*, 28(3), 112002.

Schiele P, et al. (2025) CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. *Science advances*, 11(21), eadr9331.

Purbey PK, et al. (2024) Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. *Cell reports*, 43(6), 114289.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

Mahadevan KK, et al. (2024) Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. *Science (New York, N.Y.)*, 384(6703), eadh4567.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. *Cell reports*, 43(9), 114690.

Abdelwahab T, et al. (2023) Cytotoxic CNS-associated T cells drive axon degeneration by targeting perturbed oligodendrocytes in PLP1 mutant mice. *iScience*, 26(5), 106698.

Dmello C, et al. (2023) Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. *Nature communications*, 14(1), 1566.

Golden JW, et al. (2023) Induced protection from a CCHFV-M DNA vaccine requires CD8⁺ T cells. *Virus research*, 334, 199173.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. *Cell*, 186(15), 3148.

Ravindranathan S, et al. (2022) Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. *Nature communications*, 13(1), 6418.

Démoulin T, et al. (2022) Induction of thymic atrophy and loss of thymic output by type-I interferons during chronic viral infection. *Virology*, 567, 77.

Haase S, et al. (2022) H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. *The Journal of clinical investigation*, 132(22).

John J, et al. (2022) Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. *Frontiers in immunology*, 13, 992630.

Anastasaki C, et al. (2022) Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling. *Acta neuropathologica communications*, 10(1), 120.

Huang Q, et al. (2022) The primordial differentiation of tumor-specific memory CD8⁺ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. *Cell*, 185(22), 4049.